SG11201602723RA - Crystals of diazabicyclooctane derivative and production method for crystals of diazabicyclooctane derivative - Google Patents

Crystals of diazabicyclooctane derivative and production method for crystals of diazabicyclooctane derivative

Info

Publication number
SG11201602723RA
SG11201602723RA SG11201602723RA SG11201602723RA SG11201602723RA SG 11201602723R A SG11201602723R A SG 11201602723RA SG 11201602723R A SG11201602723R A SG 11201602723RA SG 11201602723R A SG11201602723R A SG 11201602723RA SG 11201602723R A SG11201602723R A SG 11201602723RA
Authority
SG
Singapore
Prior art keywords
crystals
diazabicyclooctane derivative
production method
diazabicyclooctane
derivative
Prior art date
Application number
SG11201602723RA
Other languages
English (en)
Inventor
Takao Abe
Takeshi Furuuchi
Yoshiaki Sakamaki
Nakako Mitsuhashi
Yumiko Saito
Original Assignee
Meiji Seika Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meiji Seika Pharma Co Ltd filed Critical Meiji Seika Pharma Co Ltd
Publication of SG11201602723RA publication Critical patent/SG11201602723RA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/429Thiazoles condensed with heterocyclic ring systems
    • A61K31/43Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
SG11201602723RA 2013-10-08 2014-10-08 Crystals of diazabicyclooctane derivative and production method for crystals of diazabicyclooctane derivative SG11201602723RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013211242 2013-10-08
PCT/JP2014/076875 WO2015053297A1 (ja) 2013-10-08 2014-10-08 ジアザビシクロオクタン誘導体の結晶とその製造法

Publications (1)

Publication Number Publication Date
SG11201602723RA true SG11201602723RA (en) 2016-05-30

Family

ID=52813113

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201602723RA SG11201602723RA (en) 2013-10-08 2014-10-08 Crystals of diazabicyclooctane derivative and production method for crystals of diazabicyclooctane derivative

Country Status (21)

Country Link
US (4) US10131665B2 (hu)
EP (4) EP3613741A1 (hu)
JP (3) JP6617029B2 (hu)
KR (2) KR102487297B1 (hu)
CN (2) CN105612159A (hu)
AR (1) AR097971A1 (hu)
AU (1) AU2014332960B2 (hu)
BR (2) BR122022016622B1 (hu)
CA (2) CA3110803C (hu)
DK (1) DK3067355T3 (hu)
ES (2) ES2842225T3 (hu)
HK (2) HK1219479A1 (hu)
HU (1) HUE051925T2 (hu)
IL (2) IL244969B (hu)
MX (1) MX361659B (hu)
NZ (5) NZ757222A (hu)
RU (1) RU2695219C2 (hu)
SG (1) SG11201602723RA (hu)
TW (1) TWI673269B (hu)
WO (1) WO2015053297A1 (hu)
ZA (1) ZA201602054B (hu)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2874279C (en) 2012-05-30 2021-03-16 Meiji Seika Pharma Co., Ltd. Diazabicyclooctane derivatives useful as .beta.-lactamase inhibitor and process for preparing the same
SG11201602256UA (en) 2013-09-24 2016-04-28 Meiji Seika Pharma Co Ltd Production method for diazabicyclooctane derivative and intermediary body thereof
SG11201602723RA (en) 2013-10-08 2016-05-30 Meiji Seika Pharma Co Ltd Crystals of diazabicyclooctane derivative and production method for crystals of diazabicyclooctane derivative
TWI691499B (zh) * 2014-12-05 2020-04-21 日商明治製菓藥業股份有限公司 二氮雜雙環辛烷衍生物之結晶及安定的凍結乾燥製劑的製造法
US10208041B2 (en) * 2016-10-07 2019-02-19 Hoffman-La Roche Inc. Diazabicyclooctane compounds
KR20200030584A (ko) 2017-07-21 2020-03-20 앤타바이오 에스에이에스 화합물
KR20200091394A (ko) * 2017-09-27 2020-07-30 페도라 파마슈티칼스 인코포레이티드 디아자비시클로옥탄 유도체의 약제학적 형태 및 그의 제조방법
JP7179058B2 (ja) 2017-09-27 2022-11-28 Meiji Seikaファルマ株式会社 ジアザビシクロオクタン誘導体の剤形およびその生産プロセス
KR20200091395A (ko) * 2017-09-27 2020-07-30 페도라 파마슈티칼스 인코포레이티드 디아자비시클로옥탄 유도체의 결정형 및 그의 제조 방법
CN107941944B (zh) * 2017-11-23 2020-09-15 中山奕安泰医药科技有限公司 一种(2s,5r)-苄氧胺基哌啶-2-甲酸乙酯草酸盐的检测方法
CN107991404B (zh) * 2017-11-23 2021-01-08 中山奕安泰医药科技有限公司 一种(2s,5r)-苄氧胺基哌啶-2-甲酰胺的检测方法
EP3572411A1 (en) 2018-05-21 2019-11-27 Antabio SAS Thiazole derivatives as metallo-beta-lactamase inhibitors
EP3854786A4 (en) * 2018-09-21 2022-09-14 API Corporation PROCESS FOR THE PREPARATION OF AMINO ACID DERIVATIVES
EP4180105A1 (en) * 2020-07-13 2023-05-17 NGK Insulators, Ltd. Refining method
CN113552250A (zh) * 2021-06-30 2021-10-26 海南海灵化学制药有限公司 一种盐酸头孢唑兰的杂质检测方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5038509B1 (hu) 1970-10-21 1975-12-10
GB1589317A (en) 1977-11-24 1981-05-13 Lilly Co Eli Freeze drying cephalothin sodium
JPS6019759B2 (ja) 1977-11-24 1985-05-17 イ−ライ・リリ−・アンド・カンパニ− 非経口投予用11115152139199東京都中央区京橋2丁目3番13号
JPS60255723A (ja) 1984-05-31 1985-12-17 Ono Pharmaceut Co Ltd メシル酸ガベキサートの結晶性凍結乾燥製剤及びその製造方法
JPH07117533B2 (ja) 1985-08-28 1995-12-18 株式会社生体科学研究所 トランスフエリンおよびその用途
US20030220521A1 (en) 1989-07-27 2003-11-27 G.D. Searle & Co. Renal-selective prodrugs for control of renal sympathetic nerve activity in the treatment of hypertension
TW264475B (hu) 1991-09-20 1995-12-01 Takeda Pharm Industry Co Ltd
JP2843444B2 (ja) 1994-05-02 1999-01-06 塩野義製薬株式会社 ピロリジルチオカルバペネム誘導体の結晶,該結晶を含む凍結乾燥製剤,およびその製造方法
ES2183874T3 (es) 1994-05-02 2003-04-01 Shionogi & Co Cristal derivado de pirrolidylthiocarbapenem, preparado liofilizado conteniendo dicho cristal y procedimiento para su produccion.
DE19531874C1 (de) 1995-08-30 1996-10-02 Daimler Benz Ag Seitenwandbaugruppe für eine Kraftfahrzeugkarosserie
FR2812635B1 (fr) 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
FR2825705B1 (fr) 2001-06-08 2005-05-20 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
FR2835186B1 (fr) 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
FR2921060B1 (fr) 2007-09-14 2012-06-15 Novexel Nouveau procede de preparation d'une piperidine disubsituee et nouveaux intermediaires
DK2231667T3 (da) * 2008-01-18 2013-12-16 Merck Sharp & Dohme Beta-lactamase-hæmmere
FR2930553B1 (fr) 2008-04-29 2010-05-21 Novexel Composes azabicycliques, leur preparation et leur utilisation comme medicaments, notamment inhibiteurs de beta-lactamases
FR2936798B1 (fr) 2008-10-03 2012-09-28 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens.
WO2010126820A2 (en) 2009-04-30 2010-11-04 Merck Sharp & Dohme Corp. Preparation of alkyl esters of n-protected oxo-azacycloalkylcarboxylic acids
FR2951171A1 (fr) 2009-10-09 2011-04-15 Novexel Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation
JP2012122603A (ja) 2010-11-15 2012-06-28 Nifco Inc コネクタ装置
HUE032491T2 (hu) 2010-12-22 2017-09-28 Meiji Seika Pharma Co Ltd Optikailag aktív diaza-biciklooktán-származék és eljárás ennek elõállítására
US8772490B2 (en) 2010-12-22 2014-07-08 Meiji Seika Pharma Co., Ltd. Optically active diazabicyclooctane derivatives and process for preparing the same
TWI565706B (zh) 2011-06-17 2017-01-11 阿斯特捷利康公司 用於製備包括反-7-酮基-6-(磺酸氧基)-1,6-二氮雜雙環[3,2,1]辛烷-2-甲醯胺之雜環化合物及其鹽類之方法
RU2636147C1 (ru) 2011-08-27 2017-11-21 Вокхардт Лимитед Производные 1,6-диазабицикло[3,2,1]октан-7-она и их применение при лечении бактериальных инфекционных болезней
ES2606059T3 (es) 2011-08-30 2017-03-17 Wockhardt Limited Derivados de 1,6-diazabiciclo[3,2,1]octan-7-ona y su uso en el tratamiento de infecciones bacterianas
ES2640520T3 (es) 2011-09-13 2017-11-03 Wockhardt Limited Compuestos que contienen nitrógeno y su uso
US8796257B2 (en) 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
US9505761B2 (en) 2011-12-02 2016-11-29 Fedora Pharmaceuticals Inc. Bicyclic compounds and their use as antibacterial agents and beta-lactamase inhibitors
CA2874279C (en) 2012-05-30 2021-03-16 Meiji Seika Pharma Co., Ltd. Diazabicyclooctane derivatives useful as .beta.-lactamase inhibitor and process for preparing the same
CA2881169C (en) * 2012-08-25 2020-06-16 Wockhardt Limited 1,6-diazabicyclo [3,2,1]octan - 7 - one derivatives and their use in the treatment of bacterial infections
SG11201602256UA (en) * 2013-09-24 2016-04-28 Meiji Seika Pharma Co Ltd Production method for diazabicyclooctane derivative and intermediary body thereof
SG11201602723RA (en) 2013-10-08 2016-05-30 Meiji Seika Pharma Co Ltd Crystals of diazabicyclooctane derivative and production method for crystals of diazabicyclooctane derivative
TWI691499B (zh) 2014-12-05 2020-04-21 日商明治製菓藥業股份有限公司 二氮雜雙環辛烷衍生物之結晶及安定的凍結乾燥製劑的製造法

Also Published As

Publication number Publication date
NZ757222A (en) 2021-12-24
NZ757220A (en) 2021-12-24
NZ757221A (en) 2021-12-24
RU2016116501A (ru) 2017-11-15
JP6617029B2 (ja) 2019-12-04
KR102388529B1 (ko) 2022-04-20
JP2020007366A (ja) 2020-01-16
US20220348578A1 (en) 2022-11-03
ES2901198T3 (es) 2022-03-21
KR20220054694A (ko) 2022-05-03
BR112016006266A2 (hu) 2017-08-22
US10131665B2 (en) 2018-11-20
AU2014332960B2 (en) 2018-03-29
KR102487297B1 (ko) 2023-01-12
DK3067355T3 (da) 2021-01-04
NZ743374A (en) 2021-12-24
CN111153903A (zh) 2020-05-15
RU2016116501A3 (hu) 2018-07-12
CA2926071C (en) 2021-11-09
KR20160065871A (ko) 2016-06-09
HK1219479A1 (zh) 2017-04-07
HK1250030A1 (zh) 2018-11-23
US20190031659A1 (en) 2019-01-31
AR097971A1 (es) 2016-04-20
IL289275B2 (en) 2023-02-01
IL244969A0 (en) 2016-05-31
CA2926071A1 (en) 2015-04-16
AU2014332960A1 (en) 2016-05-26
CA3110803C (en) 2022-09-27
MX2016004506A (es) 2016-06-16
CA3110803A1 (en) 2015-04-16
JP6995810B2 (ja) 2022-01-17
EP3299370A1 (en) 2018-03-28
ES2842225T3 (es) 2021-07-13
RU2019115119A3 (hu) 2022-04-26
NZ719568A (en) 2018-06-29
EP3067355A1 (en) 2016-09-14
JP2021193107A (ja) 2021-12-23
WO2015053297A1 (ja) 2015-04-16
CN105612159A (zh) 2016-05-25
MX361659B (es) 2018-12-13
IL289275A (en) 2022-02-01
ZA201602054B (en) 2019-06-26
TWI673269B (zh) 2019-10-01
JPWO2015053297A1 (ja) 2017-03-09
RU2019115119A (ru) 2019-05-29
IL289275B (en) 2022-10-01
US10604522B2 (en) 2020-03-31
BR112016006266B1 (pt) 2022-11-16
TW201605855A (zh) 2016-02-16
BR122022016622B1 (pt) 2023-11-07
EP3067355B1 (en) 2020-12-16
EP3299370B1 (en) 2021-11-24
HUE051925T2 (hu) 2021-04-28
EP3067355A4 (en) 2017-04-26
IL244969B (en) 2022-01-01
RU2695219C2 (ru) 2019-07-22
US20160272641A1 (en) 2016-09-22
EP3613740A1 (en) 2020-02-26
EP3613741A1 (en) 2020-02-26
US11414417B2 (en) 2022-08-16
JP7182677B2 (ja) 2022-12-02
US20200181143A1 (en) 2020-06-11

Similar Documents

Publication Publication Date Title
HK1219479A1 (zh) 二氮雜二環辛烷衍生物的結晶及其製備方法
HK1219473A1 (zh) 二氮雜二環辛烷衍生物的製備方法及其中間體
GB201401248D0 (en) Method of manufacture
IL260782B (en) Pyrrole derivative crystal and method for its production
IL252691B (en) A method of producing crystals of a diazabicyclooctane derivative and a stable lyophilized preparation
GB2527996B (en) Filter and method of manufacture
PT2991817T (pt) Processo de adaptação e processo de produção para componentes fabricados por meio de slm
EP2981374A4 (en) CASTING METHOD
GB201305231D0 (en) Method of Manufacture
PL3069610T3 (pl) Ko-kryształ i sposób jego wytwarzania
HK1220969A1 (zh) 用於合成伊立替康的方法
EP2966174A4 (en) METHOD FOR PRODUCING A COMPOUND WITH HETEROCYCLES
GB201910300D0 (en) Method of and apparatuses for indentifying geological characteristics
HK1216419A1 (zh) 合成方法
EP3045443A4 (en) Method for producing -cyclolavandulal and derivative of same
EP2947075A4 (en) PROCESS FOR THE SYNTHESIS OF THIADIAZOLYLAMIDE DERIVATIVE
GB201305395D0 (en) Frame and method of manufacture thereof
HUP1300538A2 (hu) Szappan és eljárás szappan elõállítására
GB201319281D0 (en) Bed and method of manufacture thereof
GB201300370D0 (en) Method of calibrating asynchronies
SG10201701021XA (en) Method of synthesis
GB201311291D0 (en) Method of manufacture
AU2013904630A0 (en) Method of treating melanoma
GB201301262D0 (en) Method of manufacture